

Corrigendum

Corrigendum to “PLOD2 Is a Potent Prognostic Marker and Associates with Immune Infiltration in Cervical Cancer”

Guang Li ¹, **Guobing Liu** ², and **Xuefeng Wang** ¹

¹Department of Obstetrics and Gynecology, Third Affiliated Hospital of Southern Medical University, Guangzhou, 510515 Guangdong Province, China

²Department of Obstetrics and Gynecology, NanFang Hospital of Southern Medical University, Guangzhou, 510515 Guangdong Province, China

Correspondence should be addressed to Guobing Liu; guobingliu6081@sina.com and Xuefeng Wang; douwangxuefeng@163.com

Received 12 October 2021; Accepted 12 October 2021; Published 23 October 2021

Copyright © 2021 Guang Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “PLOD2 Is a Potent Prognostic Marker and Associates with Immune Infiltration in Cervical Cancer” [1], the authors wish to provide the following acknowledgement that was omitted in error:

This work was financially supported by the Natural Science Foundation of Guangdong Province (2021A1515011050) and Science and Technology Projects in Guangzhou (202102080100).

Additionally, the order of authors was listed incorrectly, and the correct order is as shown above.

References

- [1] G. Li, X. Wang, and G. Liu, “PLOD2 Is a Potent Prognostic Marker and Associates with Immune Infiltration in Cervical Cancer,” *BioMed Research International*, vol. 2021, Article ID 5512340, 2021.